Cognitive Resilience Proteins May Maintain Brain Health in Older Adults

Affectionate and cheerful senior couple
Researchers sought to identify a parsimonious set of multifunctional cortical proteins that might offer cognitive resilience and resistance to Alzheimer disease and related dementia pathologies in an older adult population.

The use of interventions that target proteins driving cognitive resilience might have the ability to offset the effects of multiple pathologies. In fact, thousands of proteins in the dorsolateral prefrontal cortex (DLPFC) might contribute to cognitive resilience. These are the findings of an analysis published in Neurology.

Cognitive resilience is a well-recognized concept. However, knowledge gaps regarding its underlying mechanisms have created difficulty in designing instruments that identify older individuals with high or low resilience. The researchers decided to test whether aggregating cortical peptides linked to cognitive resilience into an index can help to identify these older adults.

For the current study, they used a novel analytic approach to identify a parsimonious set of multifunctional cortical proteins that might offer cognitive resilience and resistance to Alzheimer disease and related dementia (ADRD) pathologies in an older adult population.

Clinical and postmortem data from a total of 1192 older decedents with a mean of 8.7±4.5 years of follow-up were included in the study. Data derived from 2 independent longitudinal cohorts—the Religious Orders Study and the Rush Memory and Aging Project—were used, including annual clinical testing, indices of ADRD pathologies, and 226 proteotypic peptides that were measured in the DLPFC.

Linear mixed effects models were used to identify peptides associated with cognitive resilience—that is, cognitive decline that was not explained by ADRD pathologies. The expression levels of these resilience peptides were aggregated into a person-specific cognitive resilience index, in order to explore its relationship with AD clinical and pathologic phenotypes.

A total of 226 separate linear mixed effects models, which were adjusted for sex, age at death, and level of education, were examined. Of these, 110 peptides were associated with the rate of cognitive decline (false discovery rate [FDR] P <.05). Overall, 52 of the 110 peptides remained associated with cognitive decline, after controlling for pathology. Of these 52 peptides, a higher index was associated with significantly slower cognitive decline (P <.001) and slower motor decline (P <.001). A majority of the resilience peptides (70%) were specific to cognitive decline, although 30% also provided resilience for motor decline.

A higher index was associated with a significantly lower burden of AD pathologies (odds ratio [OR], 0.41; P <.001), and modified the relationship between AD pathology and cognition, with a higher index modifying the negative effects of AD pathology on AD dementia proximate to death (OR, 0.70; P =.010). Up to 90% of cognitive resilience peptides were associated with AD pathologic phenotypes.

Following a review of the functions of the 52 proteins identified, the majority of the functions were mitochondrial and synaptic plasticity.

A major limitation of the current study is the fact that the results require replication in more diverse populations of patients. Although the datasets leveraged in the present analysis are large, the effects of individual genes and proteins may be quite small, thus demonstrating the utility of aggregating multiple proteins together into a summary risk score.

“Resilience proteins may be high value therapeutic targets for drug discovery of interventions that maintain brain health in aging adults via multiple pathways,” the researchers concluded.

Additional experiments in model organisms or human cell modeling will be critical for characterizing the causal mechanisms and pathways that link these resilience proteins with diverse AD clinical phenotypes, including cognitive or motor decline, as well as pathologic phenotypes such as AD.

Disclosure: One of the study authors has declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of the author’s disclosures. 

Reference  

Zammit AR, Yu L, Petyuk V, et al. Cortical proteins and individual differences in cognitive resilience in older adults. Neurology. Published online March 3, 2022. doi:10.1212/WNL.0000000000200017